Integra LifeSciences (IART) to Announce Quarterly Earnings on Wednesday

Integra LifeSciences (NASDAQ:IART) is projected to release its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to announce earnings of $0.48 per share and revenue of $417.6170 million for the quarter. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Investors can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:30 AM ET.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. The company had revenue of $391.92 million for the quarter, compared to the consensus estimate of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.Integra LifeSciences’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.41 EPS. On average, analysts expect Integra LifeSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Integra LifeSciences Price Performance

Shares of IART opened at $19.01 on Wednesday. The firm has a market cap of $1.48 billion, a price-to-earnings ratio of -2.94, a PEG ratio of 1.31 and a beta of 1.22. The stock has a 50 day moving average of $17.12 and a 200-day moving average of $13.17. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75. Integra LifeSciences has a 52 week low of $8.70 and a 52 week high of $20.26.

Institutional Trading of Integra LifeSciences

Several hedge funds have recently made changes to their positions in IART. Osaic Holdings Inc. increased its holdings in shares of Integra LifeSciences by 36.6% in the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after acquiring an additional 1,104 shares during the period. State of Tennessee Department of Treasury lifted its position in Integra LifeSciences by 7.9% in the 4th quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock valued at $332,000 after purchasing an additional 1,964 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Integra LifeSciences by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after purchasing an additional 1,975 shares during the period. Capital Fund Management S.A. boosted its stake in Integra LifeSciences by 5.7% during the 3rd quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock valued at $535,000 after purchasing an additional 1,997 shares during the period. Finally, Global Retirement Partners LLC bought a new position in Integra LifeSciences in the 4th quarter worth about $25,000. Institutional investors own 84.78% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on IART. Citigroup reissued a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Wall Street Zen lowered shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Truist Financial boosted their target price on shares of Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. BMO Capital Markets assumed coverage on shares of Integra LifeSciences in a report on Wednesday, July 8th. They set a “market perform” rating and a $19.00 target price on the stock. Finally, Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Integra LifeSciences has an average rating of “Reduce” and a consensus target price of $18.33.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.